• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vir Biotechnology Inc (NQ: VIR )

    9.410 -0.460 (-4.66%)
    Streaming Delayed Price Updated: 11:12 AM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Vir Biotechnology Inc

    < Previous 1 2 3 Next >
    Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
    From Vir Biotechnology Inc.
    Via Business Wire
    Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
    From Vir Biotechnology, Inc.
    Via Business Wire
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    From FN Media Group LLC
    Via GlobeNewswire
    Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
    From Vir Biotechnology, Inc.
    Via Business Wire
    Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
    From Vir Biotechnology, Inc.
    Via Business Wire
    Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.